Forsteo ® (teriparatide)

Forsteo® (teriparatide): Radiation After Treatment

There are no studies to describe the effect of teriparatide exposure on subsequent risk of osteosarcoma in patients that have radiation therapy after teriparatide exposure.

Detailed Information

Radiation-induced osteosarcoma is a rare, but well-recognized, complication in human radiotherapy patients. Patients who have had prior radiation therapy have an increased risk of developing a radiogenic second malignant neoplasm, including osteosarcoma, some years or decades after initial treatment.1,2


1. Kalra S, Grimer RJ, Spooner D, et al. Radiation-induced sarcomas of bone: factors that affect outcome. J Bone Joint Surg Br. 2007;89-B(6):808-813.

2. Newhauser WD, Durante M. Assessing the risk of second malignancies after modern radiotherapy. Nat Rev Cancer. 2011;11(6):438-448.

Date of Last Review: February 05, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request